• Growth guidance: The company maintained its FY27 volume growth guidance of 10% to 15% and reiterated its target to achieve ₹3,000 crore in revenue by the end of FY28.
• Product pipeline: Sampling is underway for newly launched DME—expected to contribute at least ₹200 crore in incremental revenue next year—while higher-capacity Acetonitrile and NMM plants are scheduled to go online next month.
• Subsidiary expansion: Balaji Specialty Chemicals has turned profitable and is rolling out import-substitute products TETA and TEPA, alongside a ₹600–700 crore greenfield expansion for cyanide and EDA derivatives by Q4.
• Margin sustainability: Operating margins in the 22% to 24% range are deemed sustainable after higher input and logistics costs stemming from West Asia disruptions were passed on to customers.
• Hotel business: Management ruled out divesting its hotel asset for now, noting that the business has started supporting bottom-line performance amid broader strength in the hospitality sector.